JACI中文版專欄創(chuàng)立賀詞

尹 佳（YIN Jia）

主編 中華臨床免疫和變態(tài)反應雜志

Editor-in-Chief，Chinese Journal of Allergy & Clinical Immunology

會長 中國醫(yī)師協(xié)會變態(tài)反應醫(yī)師分會

President, Chinese College of Allergy and Asthma

尊敬的各位同道和讀者們：

最近10余年，我國變態(tài)反應疾病患病人群逐年增高，老百姓希望獲得有效診治變態(tài)反應疾病的需求逐年增大。相對于龐大的臨床需求，我國專門從事變態(tài)反應疾病診治的?？漆t(yī)生很少，多數(shù)醫(yī)生分散在與變態(tài)反應疾病相關的臨床科室。變態(tài)反應疾病是全身系統(tǒng)性疾病，可涉及多個器官；從出生到暮年，變態(tài)反應疾病在其自然發(fā)展進程中表現(xiàn)形式各異，涉及兒童和成人。數(shù)以億計的患病人群和有限的變態(tài)反應?？漆t(yī)生給有效診治此類疾病帶來了挑戰(zhàn)，分散在各科從事變態(tài)反應疾病診治的醫(yī)生亟需獲得最新的資訊以提高臨床實踐水平。

《中華臨床免疫和變態(tài)反應雜志》2007 年創(chuàng)立至今已經(jīng)進入第2個10年。在過去的10年，本刊為全國從事變態(tài)反應疾病和自身免疫病的臨床醫(yī)生及研究人員提供了展示研究成果和交流信息的平臺。從2018 年起，本刊由季刊改為雙月刊。

由于地域和語言等因素，我國多數(shù)醫(yī)生不能及時獲得世界最新的變態(tài)反應疾病資訊。為更好地服務于我國變態(tài)反應和自身免疫病的臨床與科研，《中華臨床免疫和變態(tài)反應雜志》從2018 年第1期開始，引入世界變態(tài)反應疾病領域的頂級期刊，美國變態(tài)反應、哮喘和免疫學會（AAAAI）官方專業(yè)雜志—— The Journal of Allergy & Clinical Immunology （ JACI ），創(chuàng)立JACI 中文版專欄。JACI選擇《中華臨床免疫和變態(tài)反應雜志》授予首個翻譯版官方授權，充分體現(xiàn)了JACI對中國同道的重視和尊重，以及對中國患者的關注。富博思市場咨詢有限公司幫助獲得此授權。

Dear colleagues and readers:

More and more people became allergic in last decade in China, and the demand of efficient diagnosis and therapy to allergic diseases has been growing.Compared to the great requirement, specialized allergists are far from being enough in China, even many of them are scattered in other allergy associated departments. Allergic diseases are multi-systematic,involving many organs, and may take various forms during one’s whole life, affecting both adults and children. It is a challenge to effective diagnosis and treatment as limited number of allergists face to hundred millions of allergic patients, and it is in dire need of the most cutting-edge information for various physicians working on allergic diseases to improve the clinical performance.

The Chinese Journal of Allergy and Clinical immunology (CJACI) started publication in 2007, and is in its second decade now. This journal has been being a professional medium of research displaying and academic communication for physicians and researchers specializing in allergy and clinical immunology for a decade. Since 2018, it has been published from quarterly to bimonthly.

Duo to differences in regions and languages, lots of Chinese physicians cannot obtain international news and information about allergic diseases in time.Thus, aiming to provide with better service to clinic and research practice on allergy and immunology,we introduce the Chinese edition of the top journal in allergy category, The Journal of Allergy and Clinical Immunology (JACI), the official journal of the American Academy of Allergy, Asthma and Immunology (AAAAI) , since the first issue in 2018. Choosing our journal as JACI first licensee for translation indicates how much JACI values and respects our Chinese colleagues and cares Chinese patients. Focus-Insight Strategic Consulting Co. Ltd contributed in this licensing.

JACI 中文版專欄對JACI 近期發(fā)表的文章，經(jīng)過《中華臨床免疫和變態(tài)反應雜志》主編及編委會精心遴選，由優(yōu)秀青年學者和醫(yī)生團隊翻譯，并由知名專家審閱并結合國內(nèi)情況點評。希望JACI 中文版專欄的推出，能幫助我國變態(tài)反應和自身免疫病領域的醫(yī)生們提高診療水平，推動此領域的科技創(chuàng)新。

從2018 年第1期開始，我們還將推出《中華臨床免疫和變態(tài)反應雜志》微信公眾號，除向?qū)I(yè)醫(yī)生提供指南、繼續(xù)教育、會議、培訓等信息外，還將面向患者提供變態(tài)反應和自身免疫病的科普資訊。希望本雜志平臺能成為醫(yī)生和患者的朋友，大家共同進步，一起成長！

The Chinese edition will show new articles in JACI,which are well chosen by CJACI editors, translated by excellent young physicians and researchers,finally reviewed by domestic experts, and commented based on Chinese situation. We cordially hope JACI Chinese edition will improve the clinical performance of Chinese allergists and promote technological development in the field.

In the meantime, official Wechat platform of CJACI is set up, which not only provide information about guideline, education, conference, and training to doctors, but also offer popular scientific knowledge of allergic diseases to patients and the public. We hope that the CJACI platform will become a friend of both doctors and patients, with them step forward and get better together.

Zuhair K. Ballas, MD

Editor-in-Chief, Journal of Allergy and Clinical Immunology

主編 變態(tài)反應與臨床免疫學雜志

Dear Allergist/Immunologists in China：

It is my distinct honor to introduce the inaugural Special Column of the Chinese Edition of The Journal of Allergy and Clinical Immunology (JACI).Global outreach is a core mission of JACI. JACI is the official journal of the American Academy of Allergy, Asthma and Immunology representing global professionals specializing in food allergy, airway disease, skin disorders, immune deficiency and immune dysregulation.

Choosing your journal as our first licensee for translation indicates how much JACI values and respects our Chinese colleagues. The allergy and immunology specialty has been expanding greatly,resulting in continued, significant scientific contributions to the field. We are very excited to know that our licensee, Focus-Insight Strategic Consulting Co. Ltd has successfully embarked on this Special Column, together with Dr. Yin Jia, the Editor of the Chinese Journal of Allergy and Clinical Immunology. I trust that you will find the translated articles informative and intellectually stimulating.It is my sincere hope that this Special Column will evolve into a unique medium of promoting international academic exchange.

JACI publishes high-impact, cutting-edge clinical and translational research papers for allergists,immunologists, dermatologists, gastroenterologists,and other physicians and researchers interested in allergic diseases and clinical immunology.Articles cover such topics as asthma, food allergy,allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy,and other allergic and immunologic diseases. JACI content includes clinical trials and mechanistic studies that report on novel therapies, including biologics, insights into underlying mechanisms, and other discoveries that will inform our understanding of these diseases and ultimately improve the diagnosis and management of patients. With an impact factor of 13.081, JACI ranks 1st of 25 in the Allergy category and 6th of 150 in the Immunology category in the 2017 Journal Citation Reports?, published by Clarivate.

尊敬的中國變態(tài)反應學及免疫學同仁、專家們：

我格外榮幸地向大家介紹《變態(tài)反應與臨床免疫學雜志》（JACI）中文版專欄創(chuàng)立。JACI是美國變態(tài)反應、哮喘和免疫學會（AAAAI）的官方雜志，該學會匯聚了全球有關食物過敏、氣道疾病、皮膚疾病、免疫缺陷及免疫調(diào)節(jié)異常領域的專家。向全世界推廣變態(tài)反應學是JACI的核心任務。

JACI選擇《中華臨床免疫和變態(tài)反應雜志》授予其首個翻譯版官方授權，充分體現(xiàn)了JACI雜志對中國同道的重視和尊重。近年來變態(tài)反應和免疫學事業(yè)欣欣向榮、蓬勃發(fā)展，并取得了令人矚目的成就。當?shù)弥狫ACI雜志出版商和富博思市場咨詢有限公司（Focus-Insight Strategic Consulting Co. Ltd）與《中華臨床免疫和變態(tài)反應雜志》主編尹佳教授已經(jīng)開始精心籌備JACI中文版專欄時，我們感到十分激動。我相信這本雜志將會帶給各位同道一場學術的饕餮盛宴。在此，我由衷地希望本專欄能夠發(fā)展成為促進國際學術交流切磋的橋梁。

以廣大變態(tài)反應學、免疫學、皮膚病學、胃腸病學及其他領域中對變態(tài)反應疾病及臨床免疫學感興趣的醫(yī)生及研究者為對象，JACI主要刊登以上領域中最前沿的、具有高影響力的臨床醫(yī)學及轉(zhuǎn)化醫(yī)學研究成果。覆蓋以下主題：哮喘、食物過敏、過敏性鼻炎、特應性皮炎、原發(fā)性免疫缺陷、職業(yè)性及環(huán)境變態(tài)反應學，以及其他變態(tài)反應或免疫性疾病。重點報道新治療方法（如生物制劑）的臨床試驗及機制研究、發(fā)病機制的新觀點、或?qū)εR床診斷及治療有指導意義的新發(fā)現(xiàn)。科睿唯安提供的2017年期刊引證報告顯示，JACI影響因子為13.081，位列25本變態(tài)反應學雜志第1名、150本免疫學雜志第6名。

On behalf of the Editors of the JACI, we are confident that our colleagues in China will benefit from this Chinese-language Edition of the Journal. We invite you to submit your best papers to JACI for consideration for publication, and look forward to a long and fruitful collaboration.

我們僅代表JACI編委會，相信中國同道將會從JACI中文版專欄獲取有益的信息。同時，我們也力邀各位同道將高水平、高質(zhì)量的學術成果投稿至JACI雜志，以期達到一個百花齊放、百家爭鳴的長久合作目標。